Publication of accounts and temporary suspension

RNS Number : 1616O

Byotrol PLC

30 September 2019

 

Byotrol plc

PUBLICATION OF AUDITED RESULTS

FOR THE YEAR ENDED 31 MARCH 2019

TEMPORARY SUSPENSION OF TRADING IN SHARES FROM 1 OCTOBER

Byotrol plc ("Byotrol" or "the Company") has today released its Unaudited Preliminary Results for the year to 31 March 2019, which show good progress over the year.

Whilst the Directors are confident in the Unaudited Preliminary Results announcement and believe the statements are close to final form, those statements still remain subject to change, and the Group will not now be able to publish its audited annual report and accounts for the year ended 31 March 2019 (the "Accounts") by 30 September 2019 as required by Rule 19 of the AIM Rules for Companies .

 

The accounting and audit process has been extended this year by the complexities with the accounting for the Medimark acquisition and the restatement of our 2018 results for the effects of IFRS15. We are now in the process of finalising the audit process for the year and the Accounts will be published as soon as possible.

 

Dealings in the Company's ordinary shares will therefore be temporarily suspended from 7.30 a.m. tomorrow, 1 October 2019, until such time as the Accounts have been duly published in compliance with AIM Rule 19.

As set out in the preliminary results issued earlier, the Company continues to make good progress, had cash balances of £2.8m at the year end and the Directors remain confident in the outlook.

 

 

Enquiries:

Byotrol plc                                                                                 01925 742 000

David Traynor - Chief Executive

Nic Hellyer - Chief Financial Officer                                                    

finnCap

Geoff Nash / Teddy Whiley - Corporate Finance                           020 7220 0500

Richard Chambers - ECM

Notes to Editors:

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

Our patented suite of technologies delivers powerful, broad-spectrum efficacy, optimised against commonly-occurring and industry-specific pathogens.

Founded in 2005, the Company seeks to develop and commercialise advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.

For more information, please go to www.byotrol.co.uk

 

END

 

 

MSCLMMMTMBIJBBL